The global intravenous solutions market size is expected to reach USD 22.0 billion by 2030, registering a CAGR of 8% during the forecast period, according to a new report by Grand View Research, Inc. The high prevalence of preterm births, especially in emerging economies such as India and China, is expected to drive market growth during the forecast period. According to WHO, 1 in 10 babies are born preterm, and this is a global concern. Thus, the high incidence of preterm births in emerging economies, improved healthcare infrastructure, and growing healthcare expenditure & patient awareness are expected to be high impact rendering drivers of the market during the forecast period.
The use of parenteral lipid emulsions is driven by the extensive focus of various authorities to limit preterm birth mortality. As of 2021, the preterm birth rate in the U.S. was about 10.5%. Moreover, the annual societal, and economic cost was estimated at USD 25.2 billion for preterm births. Hence, the presence of many neonates requiring supplementary postbirth nutrition is expected to boost the market demand over the forecast period.
In addition, several studies justify the use of parenteral nutrition for patients suffering from malnutrition problems, which increased during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffer from acute malnourishment. Hence, the usage of parenteral nutrition products is expected to increase in the market during the pandemic.
In COVID-19-positive patients, high deficiency of specific micronutrients and vitamins has been reported to be detrimental. Thus, intravenous administration is recommended in such patients to meet the recommended dietary intake. Physicians and nutrition specialists preferred parenteral nutrition over enteral nutrition in COVID-19 patients since enteral nutrition specifically requires the setup of nasogastric tubes, which hampers the noninvasive ventilation provided to COVID-19 patients. The increased risk of nutritional solution aspiration and underfeeding in hospitalized patients for COVID-19 has led to increased adoption of parenteral nutrition.
Request a free sample copy or view report summary: Intravenous Solutions Market Report
In 2023, the Total Parenteral Nutrition (TPN) segment held a dominant market share of 66.3% and is projected to experience the highest growth rate (CAGR of 8.2%) during the forecast period. TPN involves administering a comprehensive set of nutrients through an intravenous (IV) technique
In 2023, the market was led by the single-dose amino acid solution segment, holding a significant share of 31.6%. Studies have shown that single-dose amino acids offer a complete protein source, are easily customizable with other parenteral formulations, and are straightforward to administer
In 2023, North America held a dominant market share of 41%, credited to key players, favorable regulations, and strong reimbursement in countries like the U.S. Assure Infusions, Inc. announced a USD 20 million investment to build an advanced manufacturing facility in Bartow, Florida, addressing the IV solutions demand-supply gap in the U.S.
Grand View Research has segmented the global intravenous solutions market based on product, nutrients, and region:
Intravenous Solutions Product Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)
Total Parenteral Nutrition
Peripheral Parenteral Nutrition
Intravenous Solutions Nutrients Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)
Vitamins & Minerals
Single-dose Amino Acids
Parenteral Lipid Emulsion
Intravenous Solutions Regional Scope Outlook (Volume, Thousand Units; Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players in the Intravenous Solutions Market
Fresenius Kabi AG
Otsuka Pharmaceutical Co. Ltd.
Baxter, B. Braun Melsungen AG
Vifor Pharma Management Ltd.
JW Life Science
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."